Document Type: Original Research

Authors

1 Diagnostic Laboratory Sciences and Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Bacteriology and Virology Department, Shiraz University of Medical Sciences, Shiraz, Iran

3 Ionizing and Nonionizing Radiation Protection Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Radiotherapy and Oncology, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Radiation therapy is among the most conventional cancer therapeutic modalities with effective local tumor control. However, due to the development of radio-resistance, tumor recurrence and metastasis often occur following radiation therapy. In recent years, combination of radiotherapy and gene therapy has been suggested to overcome this problem. The aim of the current study was to explore the potential synergistic effects of N-Myc Downstream-Regulated Gene 2 (NDRG2) overexpression, a newly identified candidate tumor suppressor gene, with radiotherapy against proliferation of prostate LNCaP cell line.Materials and Methods: In this study, LNCaP cells were exposed to X-ray radiation in the presence or absence of NDRG2 overexpression using plasmid PSES- pAdenoVator-PSA-NDRG2-IRES-GFP. The effects of NDRG2 overexpression, X-ray radiation or combination of both on the cell proliferation and apoptosis of LNCaP cells were then analyzed using MTT assay and flow cytometery, respectively.Results: Results of MTT assay showed that NDRG2 overexpression and X-ray radiation had a synergistic effect against proliferation of LNCaP cells. Moreover, NDRG2 overexpression increased apoptotic effect of X-ray radiation in LNCaP cells synergistically.Conclusion: Our findings suggested that NDRG2 overexpression in combination with radiotherapy may be an effective therapeutic option against prostate cancer.

Keywords

  1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-92. doi.org/10.1016/j.eururo.2012.02.054. PubMed PMID: 22424666.
  2. Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014;2:596-605. doi.org/10.1016/j.mgene.2014.07.007. PubMed PMID: 25606442. PubMed PMCID: 4287887.
  3. Hosseini M, SeyedAlinaghi S, Mahmoudi M, McFarland W. A case-control study of risk factors for prostate cancer in Iran. Acta Med Iran. 2010;48:61-6. PubMed PMID: 21137672.
  4. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556-63. doi.org/10.1093/annonc/mdn642. PubMed PMID: 19073863.
  5. Akbari ME, Hosseini SJ, Rezaee A, Hosseini MM, Rezaee I, Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev. 2008;9:549-52. PubMed PMID: 19256736.
  6. Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, et al. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urologic Oncology: Seminars and Original Investigations: Elsevier; 2014.
  7. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. International Journal of Radiation Oncology* Biology* Physics. 1997;39:1011-8. doi.org/10.1016/S0360-3016(97)00508-7.
  8. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460-8. doi.org/10.1002/(SICI)1097-0142(19990601)85:113.0.CO;2-N. PubMed PMID: 10357419.
  9. Teh BS, Aguilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, et al. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002;7:458-66. doi.org/10.1634/theoncologist.7-5-458. PubMed PMID: 12401909.
  10. Kaliberov SA, Buchsbaum DJ. Chapter seven--Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res. 2012;115:221-63. doi.org/10.1016/B978-0-12-398342-8.00007-0. PubMed PMID: 23021246. PubMed PMCID: 3664947.
  11. Yao L, Zhang J, Liu X. NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin (Shanghai). 2008;40:625-35. doi.org/10.1111/j.1745-7270.2008.00434.x. PubMed PMID: 18604454.
  12. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123:2080-6. doi.org/10.1002/ijc.23705. PubMed PMID: 18709645.
  13. Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007;358:164-9. doi.org/10.1016/j.bbrc.2007.04.089. PubMed PMID: 17470364.
  14. Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S, et al. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer. 2007;7:192. doi.org/10.1186/1471-2407-7-192. PubMed PMID: 17935612. PubMed PMCID: 2099434.
  15. Shi H, Jin H, Chu D, Wang W, Zhang J, Chen C, et al. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull. 2009;32:968-75. doi.org/10.1248/bpb.32.968. PubMed PMID: 19483300.
  16. Golestan AM, Mojtahedi ZP, Ghalamfarsa GP, Hamidinia MM, Takhshid MAP. The Effects of NDRG2 Overexpression on Cell Proliferation and Invasiveness of SW48 Colorectal Cancer Cell Line. Iran J Med Sci. 2015;40:430-9. PubMed PMID: 26379350. PubMed PMCID: 4567603.
  17. Li SJ, Wang WY, Li B, Chen B, Zhang B, Wang X, et al. Expression of NDRG2 in human lung cancer and its correlation with prognosis. Med Oncol. 2013;30:421. doi.org/10.1007/s12032-012-0421-7. PubMed PMID: 23307246. PubMed PMCID: 3586402.
  18. Faraji SN, Mojtahedi Z, Ghalamfarsa G, Takhshid MA. N-myc downstream regulated gene 2 overexpression reduces matrix metalloproteinase-2 and -9 activities and cell invasion of A549 lung cancer cell line in vitro. Iran J Basic Med Sci. 2015;18:773-9. PubMed PMID: 26557966. PubMed PMCID: 4633460.
  19. Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X, et al. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol. 2004;10:3518-21. doi.org/10.3748/wjg.v10.i23.3518. PubMed PMID: 15526377. PubMed PMCID: 4576239.
  20. Gao L, Wu GJ, Liu XW, Zhang R, Yu L, Zhang G, et al. Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene. Cancer Lett. 2011;310:94-100. doi.org/10.1016/j.canlet.2011.06.015. PubMed PMID: 21741166.
  21. Ren GF, Tang L, Yang AQ, Jiang WW, Huang YM. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy. Histol Histopathol. 2014;29:535-42. PubMed PMID: 24222185.
  22. Li R, Yu C, Jiang F, Gao L, Li J, Wang Y, et al. Overexpression of N-Myc downstream-regulated gene 2 (NDRG2) regulates the proliferation and invasion of bladder cancer cells in vitro and in vivo. PLoS One. 2013;8:e76689. doi.org/10.1371/journal.pone.0076689. PubMed PMID: 24146910. PubMed PMCID: 3797857.
  23. Horwitz EM, Hanks GE. External beam radiation therapy for prostate cancer. CA Cancer J Clin. 2000;50:349-75; quiz 76-9. doi.org/10.3322/canjclin.50.6.349. PubMed PMID: 11146903.
  24. Mosleh-Shirazi, M.A., S. Rahimi, and S. Karbasi, Medium-Term Stability of the Photon Beam Energy of An Elekta CompactTM Linear Accelerator Based on Daily Measurements of Beam Quality Factor. Iranian Journal of Medical Physics. 2016;12(4):230-234. doi 10.22038/ijmp.2016.6835
  25. Zeng M, Cerniglia GJ, Eck SL, Stevens CW. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther. 1997;8:1025-32. doi.org/10.1089/hum.1997.8.9-1025. PubMed PMID: 9189760.
  26. Yaowen Z, Yongzhen C, Jin L, Qin W. Gene therapy and radiotherapy in malignant tumor. International Journal of Radiation Medicine and Nuclear Medicine. 2008;32:247-50.
  27. Simons JW, Marshall FF. The future of gene therapy in the treatment of urologic malignancies. Urol Clin North Am. 1998;25:23-38. doi.org/10.1016/S0094-0143(05)70430-4. PubMed PMID: 9529534.
  28. Najafi M, Fardid R, Takhshid MA, Mosleh-Shirazi MA, Rezaeyan AH, Salajegheh A. Radiation-induced oxidative stress at out-of-field lung tissues after pelvis irradiation in rats. Cell J. 2016; 18(3): 340-345.
  29. Chhikara M, Huang H, Vlachaki MT, Zhu X, Teh B, Chiu KJ, et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther. 2001;3:536-42. doi.org/10.1006/mthe.2001.0298. PubMed PMID: 11319915.
  30. Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, et al. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther. 2000;2:195-203. doi.org/10.1006/mthe.2000.0114. PubMed PMID: 10985949.
  31. Kaliberov SA, Kaliberova LN, Buchsbaum DJ. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. Gene Ther. 2005;12:407-17. doi.org/10.1038/sj.gt.3302432. PubMed PMID: 15616600.